Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million

Reuters2026/08/11 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gain Therapeutics posted a Q2 net loss of USD 4.68 million, or USD 0.11 per share, narrowing from USD 0.19 per share a year earlier.
R&D expense fell 21.78% to USD 2.1 million, while G&A expense rose 8.7% to USD 2.5 million.
Cash and cash equivalents totaled USD 13.1 million at June 30, down from USD 20.8 million at Dec. 31.
FDA completed its review of the IND for rexaceract, clearing the way for a Phase 2 start in Q3 2026; final Phase 1b results are expected in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807509) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million

You may also like

Crypto prices